Bank of New York Mellon Corp Makes New $1.93 Million Investment in Beta Bionics, Inc. $BBNX

Key Points

• Bank of New York Mellon acquired 122,897 Beta Bionics shares worth approximately $1.93 million, giving it a 0.27% stake; several other institutional investors also increased or initiated positions.
• Analyst sentiment remains favorable overall, with seven Buy, four Hold and one Sell rating, resulting in a consensus “Moderate Buy” rating and average price target of $20.10.
• Beta Bionics faces a federal securities class-action lawsuit alleging misleading disclosures about the safety and performance of its iLet Bionic Pancreas; investors have until November 3, 2026 to seek lead-plaintiff status.

Bank of New York Mellon Corp acquired a new position in shares of Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 122,897 shares of the company's stock, valued at approximately $1,926,000. Bank of New York Mellon Corp owned 0.27% of Beta Bionics as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Summit Securities Group LLC acquired a new position in Beta Bionics in the 4th quarter valued at about $52,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock worth $61,000 after buying an additional 1,818 shares during the period. Strs Ohio purchased a new stake in shares of Beta Bionics in the 1st quarter valued at approximately $29,000. Legal & General Group Plc raised its holdings in shares of Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company's stock valued at $58,000 after purchasing an additional 2,639 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Beta Bionics by 630,000.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company's stock worth $192,000 after purchasing an additional 6,300 shares during the last quarter.

Analyst Ratings Changes

Several research firms recently commented on BBNX. Truist Financial increased their target price on Beta Bionics from $18.00 to $22.00 and gave the company a "buy" rating in a report on Monday, July 13th. William Blair initiated coverage on shares of Beta Bionics in a report on Friday, August 21st. They issued a "market perform" rating for the company. Weiss Ratings raised shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. The Goldman Sachs Group lifted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Finally, Bank of America reduced their price target on shares of Beta Bionics from $23.00 to $11.00 and set a "neutral" rating for the company in a research report on Monday, May 18th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $20.10.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The lawsuit alleges that Beta Bionics made false or misleading statements, or failed to disclose material adverse information, regarding the safety and performance of its iLet Bionic Pancreas automated insulin-delivery system. The allegations have not been proven. Holzer & Holzer investor alert
• Negative Sentiment: Several firms reported that a federal securities class action was filed in the Central District of California on behalf of investors who acquired BBNX shares during the alleged class period, generally July 30, 2025, through February 24, 2026. One notice cited June 30, 2025 as the starting date, indicating that investors should review the court filings for the definitive period. Gainey McKenna & Egleston lawsuit announcement
• Negative Sentiment: Investors have until November 3, 2026 to seek appointment as lead plaintiff. The deadline reminders from Johnson Fistel, Faruqi & Faruqi, Rosen Law Firm and other firms are largely duplicative announcements, rather than separate newly disclosed lawsuits, but they increase visibility around the legal claims. Faruqi & Faruqi deadline alert

Insider Buying and Selling

In related news, insider Mike Mensinger sold 4,375 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the sale, the insider directly owned 180,040 shares of the company's stock, valued at $3,440,564.40. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the transaction, the insider owned 169,628 shares in the company, valued at approximately $3,241,591.08. This trade represents a 2.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 33,262 shares of company stock valued at $604,002 in the last ninety days. Company insiders own 5.30% of the company's stock.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $19.33 on Wednesday. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The company has a market capitalization of $869.66 million, a P/E ratio of -11.72 and a beta of 3.37. The company's fifty day moving average is $17.29 and its two-hundred day moving average is $13.73.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. As a group, equities analysts expect that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

Want to see what other hedge funds are holding BBNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beta Bionics, Inc. (NASDAQ:BBNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.